Literature DB >> 31577379

Breast cancer statistics, 2019.

Carol E DeSantis1, Jiemin Ma1, Mia M Gaudet2, Lisa A Newman3, Kimberly D Miller1, Ann Goding Sauer1, Ahmedin Jemal1, Rebecca L Siegel1.   

Abstract

This article is the American Cancer Society's biennial update on female breast cancer statistics in the United States, including data on incidence, mortality, survival, and screening. Over the most recent 5-year period (2012-2016), the breast cancer incidence rate increased slightly by 0.3% per year, largely because of rising rates of local stage and hormone receptor-positive disease. In contrast, the breast cancer death rate continues to decline, dropping 40% from 1989 to 2017 and translating to 375,900 breast cancer deaths averted. Notably, the pace of the decline has slowed from an annual decrease of 1.9% during 1998 through 2011 to 1.3% during 2011 through 2017, largely driven by the trend in white women. Consequently, the black-white disparity in breast cancer mortality has remained stable since 2011 after widening over the past 3 decades. Nevertheless, the death rate remains 40% higher in blacks (28.4 vs 20.3 deaths per 100,000) despite a lower incidence rate (126.7 vs 130.8); this disparity is magnified among black women aged <50 years, who have a death rate double that of whites. In the most recent 5-year period (2013-2017), the death rate declined in Hispanics (2.1% per year), blacks (1.5%), whites (1.0%), and Asians/Pacific Islanders (0.8%) but was stable in American Indians/Alaska Natives. However, by state, breast cancer mortality rates are no longer declining in Nebraska overall; in Colorado and Wisconsin in black women; and in Nebraska, Texas, and Virginia in white women. Breast cancer was the leading cause of cancer death in women (surpassing lung cancer) in four Southern and two Midwestern states among blacks and in Utah among whites during 2016-2017. Declines in breast cancer mortality could be accelerated by expanding access to high-quality prevention, early detection, and treatment services to all women.
© 2019 American Cancer Society.

Entities:  

Keywords:  breast neoplasms; epidemiology; health disparities; incidence; molecular subtype; mortality

Mesh:

Year:  2019        PMID: 31577379     DOI: 10.3322/caac.21583

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  716 in total

1.  Revisiting Hormonal Control of Vascular Injury and Repair.

Authors:  Daniel Pérez-Cremades; Henry S Cheng; Mark W Feinberg
Journal:  Circ Res       Date:  2020-12-03       Impact factor: 17.367

Review 2.  Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics.

Authors:  Elham Hatami; Meena Jaggi; Subhash C Chauhan; Murali M Yallapu
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-05-31       Impact factor: 10.680

3.  X-ray-induced acoustic computed tomography for guiding prone stereotactic partial breast irradiation: a simulation study.

Authors:  Yue Zheng; Pratik Samant; Jack Merill; Yong Chen; Salahuddin Ahmad; Dengwang Li; Liangzhong Xiang
Journal:  Med Phys       Date:  2020-06-15       Impact factor: 4.071

Review 4.  Comprehensive Review of Molecular Mechanisms and Clinical Features of Invasive Lobular Cancer.

Authors:  Nikhil Pramod; Akanksha Nigam; Mustafa Basree; Resham Mawalkar; Saba Mehra; Neelam Shinde; Gary Tozbikian; Nicole Williams; Sarmila Majumder; Bhuvaneswari Ramaswamy
Journal:  Oncologist       Date:  2021-03-16

5.  Clinical value of serum biomarkers CA153, CEA, and white blood cells in predicting sentinel lymph node metastasis of breast cancer.

Authors:  Yuan Fan; Xiuyuan Chen; Hongjiang Li
Journal:  Int J Clin Exp Pathol       Date:  2020-11-01

Review 6.  Breast cancer liver metastasis: current and future treatment approaches.

Authors:  Narmeen S Rashid; Jacqueline M Grible; Charles V Clevenger; J Chuck Harrell
Journal:  Clin Exp Metastasis       Date:  2021-03-06       Impact factor: 5.150

7.  Arctigenin-mediated cell death of SK-BR-3 cells is caused by HER2 inhibition and autophagy-linked apoptosis.

Authors:  Min-Gu Lee; Kyu-Shik Lee; Kyung-Soo Nam
Journal:  Pharmacol Rep       Date:  2021-03-07       Impact factor: 3.024

8.  27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression.

Authors:  Liqian Ma; Lawrence Wang; Adam T Nelson; Chaeyeon Han; Sisi He; Madeline A Henn; Karan Menon; Joy J Chen; Amy E Baek; Anna Vardanyan; Sayyed Hamed Shahoei; Sunghee Park; David J Shapiro; Som G Nanjappa; Erik R Nelson
Journal:  Cancer Lett       Date:  2020-08-28       Impact factor: 8.679

9.  Analysis of the Transcriptome: Regulation of Cancer Stemness in Breast Ductal Carcinoma In Situ by Vitamin D Compounds.

Authors:  Naing Lin Shan; Audrey Minden; Philip Furmanski; Min Ji Bak; Li Cai; Roman Wernyj; Davit Sargsyan; David Cheng; Renyi Wu; Hsiao-Chen D Kuo; Shanyi N Li; Mingzhu Fang; Hubert Maehr; Ah-Ng Kong; Nanjoo Suh
Journal:  Cancer Prev Res (Phila)       Date:  2020-05-28

10.  High-background parenchymal enhancement in the contralateral breast is an imaging biomarker for favorable prognosis in patients with triple-negative breast cancer treated with chemotherapy.

Authors:  Chuanhui Xu; Jinhui Yu; Feifei Wu; Xuemei Li; Dongmin Hu; Guiming Chen; Gang Wu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.